Eniluracil
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 201250

CAS#: 59989-18-3

Description: Eniluracil, also known as GW776 and GW776C85, is an orally active and irreversible inhibitor of dihydropyrimidine dehydrogenase. Eniluracil inhibits dihydropyrimidine dehydrogenase, the rate-limiting enzyme that catabolizes and inactivates 5-fluorouracil (5-FU) in the liver. Co-administration of ethynyluracil permits the oral administration of 5-FU. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).


Price and Availability

Size
Price

10mg
USD 50
100mg
USD 250
1g
USD 950
Size
Price

25mg
USD 90
200mg
USD 350
2g
USD 1650
Size
Price

50mg
USD 150
500mg
USD 550
5g
Ask price

Enilracil, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received. Note: Lead time for order > 1g may be 2 months.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 201250
Name: Eniluracil
CAS#: 59989-18-3
Chemical Formula: C6H4N2O2
Exact Mass: 136.02728
Molecular Weight: 136.11
Elemental Analysis: C, 52.95; H, 2.96; N, 20.58; O, 23.51


Synonym: 776C85; DH300004; GW776; GW-776; GW 776; GW-776C85; GW 776C85; GW776C85; NSC 687296; 5-ethynyluracil; ethynyluracil.

IUPAC/Chemical Name: 5-ethynylpyrimidine-2,4(1H,3H)-dione.

InChi Key: JOZGNYDSEBIJDH-UHFFFAOYSA-N

InChi Code: InChI=1S/C6H4N2O2/c1-2-4-3-7-6(10)8-5(4)9/h1,3H,(H2,7,8,9,10)

SMILES Code: O=C1NC(C(C#C)=CN1)=O


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


Additional Information

Eniluracil plus 5‑FU was previously being developed by GlaxoSmithKline (GSK). Although the therapy was successful in Phase I and Phase II clinical trials, it tended to produce less antitumor activity than the control therapy in two Phase III trials. Development was subsequently stopped. Since then, Adherex has learned that with the dose and schedule used in the previous GSK Phase III trials may not have been optimal. Preclinical studies have shown that when eniluracil is present in high ratios to 5‑FU, it decreases the antitumor activity. In the Phase III trials, the eniluracil:5‑FU ratio was 10:1. see: http://adherex.com/product-candidate/eniluracil-clinical-development/
 
Eniluracil is a potent inactivator of dihydropyrimidine dehydrogenase (uracil reductase), the enzyme that rapidly catabolizes 5-fluorouracil (5-FU). Although eniluracil in combination with 5-FU was promising in phase I and II studies, in 2 multicenter phase III colorectal cancer studies, eniluracil dosed in a 10-to-1 ratio to 5-FU produced less antitumor benefit than the std. regimen of 5-FU/leucovorin without eniluracil.  Clinical Colorectal Cancer (2010), 9(1), 52-54.
 
 


References